Put Options

16 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$51.18 - $63.75 $1.54 Million - $1.91 Million
30,000 New
30,000 $1.82 Million
Q3 2023

Nov 14, 2023

BUY
$57.77 - $65.93 $1.73 Million - $1.98 Million
30,000 New
30,000 $1.73 Million
Q3 2022

Nov 14, 2022

BUY
$66.18 - $82.86 $1.99 Million - $2.49 Million
30,000 New
30,000 $2 Million
Q2 2022

Aug 15, 2022

SELL
$66.18 - $83.18 $3.97 Million - $4.99 Million
-60,000 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$66.02 - $79.71 $330,100 - $398,549
5,000 Added 9.09%
60,000 $4.77 Million
Q4 2021

Feb 11, 2022

SELL
$63.34 - $74.11 $10.8 Million - $12.6 Million
-170,000 Reduced 75.56%
55,000 $4.04 Million
Q3 2021

Nov 12, 2021

SELL
$68.67 - $84.02 $3.78 Million - $4.62 Million
-55,000 Reduced 19.64%
225,000 $15.5 Million
Q2 2021

Aug 16, 2021

BUY
$79.87 - $87.53 $14.8 Million - $16.2 Million
185,000 Added 194.74%
280,000 $23.6 Million
Q1 2021

May 17, 2021

BUY
$76.02 - $100.5 $3.72 Million - $4.92 Million
49,000 Added 106.52%
95,000 $7.72 Million
Q4 2020

Feb 16, 2021

BUY
$80.74 - $97.7 $3.71 Million - $4.49 Million
46,000 New
46,000 $4 Million
Q3 2020

Nov 16, 2020

SELL
$85.07 - $109.69 $2.55 Million - $3.29 Million
-30,000 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$74.18 - $108.93 $370,900 - $544,650
-5,000 Reduced 14.29%
30,000 $3.12 Million
Q4 2019

Feb 13, 2020

BUY
$73.04 - $95.72 $1.46 Million - $1.91 Million
20,000 Added 133.33%
35,000 $3.06 Million
Q2 2019

Aug 13, 2019

BUY
$73.52 - $88.7 $1.1 Million - $1.33 Million
15,000 New
15,000 $1.27 Million
Q2 2018

Aug 14, 2018

SELL
$60.85 - $83.98 $9.93 Million - $13.7 Million
-163,200 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$83.06 - $100.98 $13.6 Million - $16.5 Million
163,200 New
163,200 $13.6 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.6B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.